An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus.

Trial Profile

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jun 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01876849).
    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top